-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Compugen (NASDAQ:CGEN) Stock Rating Upgraded by StockNews.com
Compugen (NASDAQ:CGEN) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.
CGEN has been the subject of a number of other research reports. JMP Securities reduced their target price on Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a report on Monday, August 8th. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Truist Financial cut their price objective on Compugen from $14.00 to $4.00 and set a buy rating for the company in a report on Tuesday, August 23rd. Finally, Oppenheimer cut their price objective on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Compugen currently has a consensus rating of Moderate Buy and an average price target of $6.20.
Get Compugen alerts:Compugen Stock Performance
Shares of NASDAQ:CGEN opened at $0.91 on Tuesday. The stock has a fifty day moving average of $1.41 and a 200-day moving average of $2.04. The company has a market capitalization of $79.02 million, a PE ratio of -2.34 and a beta of 2.15. Compugen has a one year low of $0.91 and a one year high of $7.48.
Compugen (NASDAQ:CGEN – Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. During the same period in the previous year, the business posted ($0.11) earnings per share. As a group, research analysts forecast that Compugen will post -0.43 EPS for the current fiscal year.Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in shares of Compugen by 1.9% in the first quarter. Taylor Frigon Capital Management LLC now owns 672,055 shares of the biotechnology company's stock valued at $2,164,000 after purchasing an additional 12,769 shares in the last quarter. Eagle Rock Investment Company LLC acquired a new stake in Compugen during the 4th quarter worth $83,000. Qube Research & Technologies Ltd acquired a new stake in Compugen during the 1st quarter worth $85,000. WMS Partners LLC acquired a new stake in Compugen during the 1st quarter worth $74,000. Finally, Antonetti Capital Management LLC grew its holdings in Compugen by 41.5% during the 1st quarter. Antonetti Capital Management LLC now owns 350,671 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 102,771 shares during the period.
About Compugen
(Get Rating)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.
斯托克新聞網在週二上午發佈的一份研究報告中將納斯達克(CDH Investments:CGEN-GET Rating)的股票評級從賣出上調為持有。
CGEN has been the subject of a number of other research reports. JMP Securities reduced their target price on Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a report on Monday, August 8th. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Truist Financial cut their price objective on Compugen from $14.00 to $4.00 and set a buy rating for the company in a report on Tuesday, August 23rd. Finally, Oppenheimer cut their price objective on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Compugen currently has a consensus rating of Moderate Buy and an average price target of $6.20.
CGEN已經成為許多其他研究報告的主題。JMP證券將其對Compugen的目標價從8.00美元下調至4.00美元,並在8月8日週一的一份報告中為該公司設定了表現優於市場的評級。傑富瑞金融集團將Compugen的評級從買入下調至持有,併為該公司設定了2.00美元的目標價。在8月5日星期五的一份報告中。Truist Financial在8月23日(星期二)的一份報告中將Compugen的目標價從14.00美元下調至4.00美元,併為該公司設定了買入評級。最後,奧本海默將Compugen的目標價從14.00美元下調至12.00美元,並在8月8日星期一的一份報告中為該公司設定了表現優於大盤的評級。兩名研究分析師對該股的評級為持有,四名分析師對該公司的評級為買入。根據MarketBeat.com的數據,Compugen目前的共識評級為中等買入,平均目標價為6.20美元。
Compugen Stock Performance
Compugen股票表現
Shares of NASDAQ:CGEN opened at $0.91 on Tuesday. The stock has a fifty day moving average of $1.41 and a 200-day moving average of $2.04. The company has a market capitalization of $79.02 million, a PE ratio of -2.34 and a beta of 2.15. Compugen has a one year low of $0.91 and a one year high of $7.48.
納斯達克:cgen週二開盤報0.91美元。該股的50日移動均線為1.41美元,200日移動均線為2.04美元。該公司市值為7,902萬美元,市盈率為-2.34,貝塔係數為2.15。Compugen的一年低點為0.91美元,一年高位為7.48美元。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in shares of Compugen by 1.9% in the first quarter. Taylor Frigon Capital Management LLC now owns 672,055 shares of the biotechnology company's stock valued at $2,164,000 after purchasing an additional 12,769 shares in the last quarter. Eagle Rock Investment Company LLC acquired a new stake in Compugen during the 4th quarter worth $83,000. Qube Research & Technologies Ltd acquired a new stake in Compugen during the 1st quarter worth $85,000. WMS Partners LLC acquired a new stake in Compugen during the 1st quarter worth $74,000. Finally, Antonetti Capital Management LLC grew its holdings in Compugen by 41.5% during the 1st quarter. Antonetti Capital Management LLC now owns 350,671 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 102,771 shares during the period.
機構投資者最近調整了對該公司的持股。Taylor Frigon Capital Management LLC在第一季度增持了1.9%的Compugen股票。Taylor Frigon Capital Management LLC現在持有這家生物技術公司672,055股股票,價值2,164,000美元,上個季度又購買了12,769股。Eagle Rock Investment Company LLC在第四季度收購了Compugen價值83,000美元的新股份。Qube Research&Technologies Ltd在第一季度收購了Compugen價值8.5萬美元的新股份。WMS Partners LLC在第一季度收購了Compugen價值7.4萬美元的新股份。最後,Antonetti Capital Management LLC在第一季度增持了41.5%的Compugen股份。Antonetti Capital Management LLC在此期間額外收購了102,771股,現在擁有350,671股這家生物技術公司的股票,價值1,129,000美元。
About Compugen
關於Compugen
(Get Rating)
(獲取評級)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Compugen有限公司是一家臨牀階段的治療發現和開發公司,在以色列、美國和歐洲研究、開發和銷售候選治療和產品。該公司的免疫腫瘤學產品線包括COM701,一種用於治療實體腫瘤的抗PVRIG抗體,處於第一階段臨牀研究;COM902,一種針對TIGIT的治療性抗體,正處於對晚期癌症患者的單一療法的第一階段臨牀研究;Bapotulimab,一種針對ILDR2的治療性抗體,正處於實體腫瘤患者的第一階段臨牀研究;以及AZD2936,一種新型的抗TIGIT/PD-1雙特異性抗體,正處於針對晚期或轉移性非小細胞肺癌患者的I/II臨牀研究。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- 免費獲取StockNews.com關於Compugen的研究報告(CGEN)
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但並未出局
- 福特在第三季度發出警告後是否正在反彈
- 如果你渴望價值,那就嚐嚐露絲的好客之道吧
- AMD股票是不是跌得太厲害了?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Compugen Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Compugen和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧